Contact Us

TOURISM NEWS

Vietnamese Party General Secretary - H.E. To Lam and Vietnam - Indonesia high-level delegation witness strategic partnership signing between TTC AgriS and Sungai Budi Group

Mar 12, 2025

JAKARTA,Indonesia,March 12,2025-- Under the witness of Vietnamese Party General Secretary - H.E. To Lam and Senior Ministers from both nations,on March 10th,TTC AgriS (Thanh Thanh Cong – Bien Hoa Joi

AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration

Mar 12, 2025

Launch of Major Product Expected to Significantly Drive Performance Growth HONG KONG,March 12,2025-- AIM Vaccine Co.,Ltd. (06660.HK),a leading PRC vaccine company,published an announcement on March 12

Ericsson Annual Report on Form 20-F filed with the SEC

Mar 12, 2025

STOCKHOLM,March 12,2025-- On March 11,2025,Ericsson (NASDAQ: ERIC) filed its Annual Report on Form 20-F for the year ended December 31,2024,with the U.S. Securities and Exchange Commission (SEC).

Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch for NASH

Mar 12, 2025

RAICHUR,India,March 12,2025--Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED),a leading API and formulation manufacturer,announces that the Subject Expert Committee (SEC) of CDSCO has approved

Prosecutors' foreign-related work in focus

Mar 11, 2025

BEIJING,March 8,2025-- A news report fromchinadaily.com.cn: The intensified multilateral and bilateral exchanges between China and other countries and regions have led to an increase in foreign-relat

U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®

Mar 11, 2025

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating compar

1 ... 45 46 47 48 49 50 51 ... 358